Fosaprepitant versus aprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: a multicenter, randomized, double-blind, double-simulated, positive-controlled phase III trial
Zhonghan Zhang,Yunpeng Yang,Ping Lu,Xiaoqin Li,Jianhua Chang,Rongsheng Zheng,Lei Zhou,Shaoshui Chen,Xiaopin Chen,Biyong Ren,Wei Gu,Xiaodong Jiang,Jiyong Peng,Miaolong Huang,Guosheng Feng,Peng Shen,Qingyuan Zhang,Baihong Zhang,Yan Huang,Jingdong He,Yinglan Chen,Jingxu Cao,Hong Wang,Wei Li,Huiping Wan,Kejun Nan,Zijun Liao,Cuiying Zhang,Zhong Lin,Diansheng Zhong,Qing Xu,Hailong Liu,Tao Sun,Yanming Deng,Li Zhang
DOI: https://doi.org/10.21037/atm.2019.12.158
IF: 3.616
2020-01-01
Annals of Translational Medicine
Abstract:Background: To establish the role of antiemetic therapy with neurolcinin-1 (NK-1) receptor antagonists (RAs) in Chinese patients associated with cisplatin-base chemotherapy regimens, this study evaluated the efficacy and safety of single-dose intravenous fosaprepitant-based triple antiemetic regimen to a 3-day orally aprepitant-based antiemetic triplet schedule for the prevention of chemotherapy-induced nausea and vomiting (CINV). Methods: A randomized, double-blind, positive-control design was used to test the noninferiority of fosaprepitant towards aprepitant. Patients receiving cisplatin-base (>= 50 mg/m(2)) chemotherapy were administrated palonosetron and dexamethasone with a single-dose fosaprepitant (150 mg on day 1) or a standard aprepitant regimen (125 mg on day 1, 80 mg on day 2 and day 3). The primary endpoint was complete response (CR) during overall phase (OP). Secondary endpoints include CR during acute phase (AP) and delayed phase (DP), no vomiting and no significant nausea during OP, AP and DP. Accrual of 324 patients per treatment arm was planned to confirm noninferiority with expected CR of 75% and noninferiority margin of minus 10 percentage points. Results: A total of 648 patients were randomly assigned, and 644 were evaluable for efficacy and safety. Antiemetic efficacy of CR during the OP with fosaprepitant and aprepitant was equivalent (71.96% versus 69.35%, P=0.4894). And a between-group difference of 2.61 percentage points was finally achieved (95% CI, -4.42 to 9.64) within predefined bounds for noninferiority (primary end point achieved). Both regimens were well tolerated and commonly reported adverse events (>= 1%) were similar between these two group. Conclusions: Single-dose intravenous fosaprepitant (150 mg) combined with palonosetron and dexamethasone was well tolerated and demonstrated noninferior control of CINV to aprepitant-based triple regimen in Chinese patients treating with cisplatin-base chemotherapy.